The value of the cytochemical β-glucuronidase (β-gluc.) reaction in the differential diagnosis of acute leukaemia was assessed in a series of 100 adult patients. A purely granular type of reaction was observed in 7 out of 8 cases of lymphoblastic leukaemia and in 2 of 11 cases of acute leukaemia of uncertain type. Such an exclusively granular reaction was never seen in other types of acute leukaemia. In most cases of myeloblastic, promyelocytic, myelomonocytic and monocytic leukaemia, a positive staining reaction was noted which was either diffuse or a combination of diffuse and finely granular. The cells of one patient with lymphoblastic leukaemia were negative for β-gluc. A coarsely granular PAS reaction was noted in 5 cases of lymphoblastic leukaemia including the one with negative β-gluc. reaction. Our results show that the β-gluc. reaction is of definite value in the diagnosis of lymphoblastic leukaemia, and that it is probably more sensitive than the PAS reaction. In monocytic or myelomonocytic leukaemia, the pattern and intensity of staining did not differ appreciably from that seen in myeloblastic leukaemia.

Keywords:
Acute leukaemia, β Glucuronidase, Cytochemistry, Lymphoblastic leukaemia
This content is only available via PDF.
© 1975 S. Karger AG, Basel
1975
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.